Latest Industry Insights

Technology Networks spoke with Dr. Bertram Brenig and Illumina to find out more about how studying genetic differences in honey bees will improve breeding programs, and how Illumina will support this research.

In this interview, Dr. Huang discusses the advantages of the direct PCR approach and explains why uptake has so far not been greater.

Clinicians have been using AMH in treatments related to reproductive health for over 20 years. High-quality diagnostic assays have come on in leaps and bounds over that time, continuing to provide precise insights to support clinical decisions made in the areas of reproductive aging, fertility and pregnancy monitoring.

Technology Networks recently spoke with Dr. Nick Downey, NGS collaborations lead at IDT, to learn more about the ways that NGS is being used as part of the response to the pandemic and gain insights into how and why this varies globally.

In this interview, Dr. Koh Meng Yong discusses the advantages of using lentiviral vectors and some of the applications they are enabling.

To learn how cell cultured human milk is produced and how it compares to mothers’ milk, Technology Networks spoke to Shayne Guiliano, CEO of 108Labs. In this interview, Shayne also highlights the impact that scaling up the technology will have and shares his thoughts on what could be in store for the future of cellular agriculture.

In the search to discover new therapeutic approaches for AD, scientists are finding new inspiration where others may have never thought to look: cancer research trends.

The biotechnology company Angany recently announced the successful production of neutralizing monoclonal antibodies (NAbs) derived from the plasma of COVID-19 patients using its plant-based system. Angany has now joined forces with global technology company Phylloceuticals to leverage its plant-made commercial production system, to rapidly scale up commercial manufacturing.

Non-invasive stimulation company Nēsos recently announced that its “e-mmunotherapy” earbud has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for patients with rheumatoid arthritis (RA). We spoke to Konstantinos Alataris, president and CEO of Nēsos, to find out more about the company's device and its potential applications.

In this article, we discuss the role of anti-PLA2R and anti-THSD7A antibodies in the diagnosis of primary membranous nephropathy and highlight why there is a need to measure these biomarkers before kidney transplants.